Wednesday, July 8, 2026

pharma · MASH · MASLD · SGMT

Sagimet Biosciences

Sagimet Biosciences is a pharma organization headquartered in San Mateo, USA. It trades on NYSE under ticker SGMT. Primary therapeutic focus areas include MASH, MASLD, Metabolic Syndrome, Non-alcoholic Steatohepatitis, K

155 Bovet Rd, Suite 303, San Mateo, California 94402, US HQ
27 Employees
Public company Type
SGMT · NYSE Ticker
Company details
Status
Public
HQ
155 Bovet Rd, Suite 303, San Mateo, California 94402, US
Employees
27
Programs
12
Drugs
4
Patents
1
Clinical program

TVB-2640

Phase 1 · small molecule · Prostatic Neoplasms, Castration-Resistant

TVB-2640 for Prostatic Neoplasms, Castration-Resistant is a Phase 1 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).

← All Sagimet Biosciences projects Phase 1 small molecule active

Internal code 22-08025117

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Sagimet Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Prostatic Neoplasms, Castration-Resistant
Status
active
Trials
1

Clinical trials